ADCs in HER2-negative Metastatic Breast Cancer
Belgian treatment landscape and interactive case studies
Expert panel:
Dr. Ana C. Garrido-Castro, MD, Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, Boston, MA
Dr. Evandro de Azambuja, MD, PhD, Jules Bordet Institute, Brussels
Dr. Kevin Punie, MD, Ziekenhuis aan de Stroom, Antwerp
Dr. Donatienne Taylor, MD, Centre Hospitalier Universitaire de l'Université Catholique de Louvain à Namur, Namur
Dr. Evandro de Azambuja, MD, PhD, Jules Bordet Institute, Brussels
Dr. Kevin Punie, MD, Ziekenhuis aan de Stroom, Antwerp
Dr. Donatienne Taylor, MD, Centre Hospitalier Universitaire de l'Université Catholique de Louvain à Namur, Namur
ADCs in HER2-negative Metastatic Breast Cancer
Belgian treatment landscape and interactive case studies
This 90-minute symposium features clinical case discussions and Belgian perspectives on current and evolving treatment strategies with ADCs in mTNBC and HR+/HER2-negative metastatic breast cancer.
🎯 Learning objectives of this expert discussion
🎓 Accreditation points available for participants
👩⚕️ Please note: this symposium is intended for healthcare professionals only.
Expert panel:
Dr. Ana C. Garrido-Castro, MD, Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, Boston, MA
Dr. Evandro de Azambuja, MD, PhD, Jules Bordet Institute, Brussels
Dr. Kevin Punie, MD, Ziekenhuis aan de Stroom, Antwerp
Dr. Donatienne Taylor, MD, Centre Hospitalier Universitaire de l'Université Catholique de Louvain à Namur, Namur
This 90-minute symposium features clinical case discussions and Belgian perspectives on current and evolving treatment strategies with ADCs in mTNBC and HR+/HER2-negative metastatic breast cancer.
🎯 Learning objectives of this expert discussion
- Gain an overview of the current treatment options with ADCs in mTNBC and HR+/HER2-negative metastatic breast cancer, as well as the evolving ADC landscape
- Understand the recent updates from the ESMO and NCCN guidelines for mTNBC and HR+/HER2-negative metastatic breast cancer
- Learn how to manage ADC-related adverse events
- Discuss clinical strategies through patient case studies
🎓 Accreditation points available for participants
👩⚕️ Please note: this symposium is intended for healthcare professionals only.
Expert panel:
Dr. Ana C. Garrido-Castro, MD, Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, Boston, MA
Dr. Evandro de Azambuja, MD, PhD, Jules Bordet Institute, Brussels
Dr. Kevin Punie, MD, Ziekenhuis aan de Stroom, Antwerp
Dr. Donatienne Taylor, MD, Centre Hospitalier Universitaire de l'Université Catholique de Louvain à Namur, Namur
This course is currently available for physicians only.
